`
`
`
`
`
`
`Filed: August 29, 2019
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`MYLAN PHARMACEUTICALS INC.
`Petitioner,
`
`v.
`
`BIOGEN MA, INC.
`Patent Owner.
`
`
`
`Patent No. 8,399,514
`
`
`
`
`Inter Partes Review IPR2018-01403
`
`
`
`
`
`
`PETITIONER’S AMENDED NOTICE OF DEPOSITION OF
`GILMORE O’NEILL, M.D.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.53, Petitioner Mylan Pharmaceuticals Inc.,
`
`hereby provides notice that it will cross-examine Dr. Gilmore O’Neill, a witness of
`
`Patent Owner Biogen MA, Inc. The cross-examination will begin at 9:00 a.m. on
`
`September 13, 2019 at the law offices of Finnegan, Henderson, Farabow, Garrett &
`
`Dunner, LLP, Two Seaport Lane, Boston, MA 02210-2001. The parties have
`
`agreed on this date for the cross-examination of Dr. O’Neill.
`
`The cross-examination will be recorded by stenographic means by a court
`
`reporter licensed to administer oaths, and will also be recorded using audio and/or
`
`visual means.
`
`By:
`
`
`
`
`
`Dated: August 29, 2019
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`PERKINS COIE LLP
`/s/ Emily J. Greb
`
`
`
`
`Emily J. Greb
`Reg. No. 68,244
`Perkins Coie LLP
` 33 East Main Street, Suite 201
`Madison, WI 53703
`Telephone: (608) 663-7494
`E-mail: EGreb@perkinscoie.com
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that the foregoing PETITIONER’S
`AMENDED NOTICE OF DEPOSITION OF GILMORE O’NEILL, M.D. was
`served electronically via e-mail as follows:
`
`Patent Owner:
`
`Barbara C. McCurdy
`Mark J. Feldstein
`Erin M. Sommers
`Pier D. DeRoo
`Cora R. Holt
`Finnegan, Henderson, Farabow, Garrett
`& Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001
`(202) 408-4047
`barbara.mccurdy@finnegan.com
`mark.feldstein@finnegan.com
`erin.sommers@finnegan.com
`pier.deroo@finnegan.com
`cora.holt@finnegan.com
`
`
`Dated: August 29, 2019
`
`
`
`
`
`
`
`
`
`
`
`/s/Emily J. Greb
`Emily J. Greb
`Reg. No. 68,244
`Counsel for Petitioner Mylan Pharmaceuticals Inc.
`
`